Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Adhera Therapeutics, Inc. | atrx-20191231xexx321.htm |
| EX-31.2 - EXHIBIT 31.2 - Adhera Therapeutics, Inc. | atrx-20191231xexx312.htm |
| EX-31.1 - EXHIBIT 31.1 - Adhera Therapeutics, Inc. | atrx-20191231xexx311.htm |
| EX-23.1 - EXHIBIT 23.1 - Adhera Therapeutics, Inc. | atrx-20191231xex231.htm |
| EX-21.1 - EXHIBIT 21.1 - Adhera Therapeutics, Inc. | atrx-20191231xex211.htm |
| EX-4.10 - EXHIBIT 4.10 - Adhera Therapeutics, Inc. | atrx-20191231xexx410.htm |
| 10-K - 10-K - Adhera Therapeutics, Inc. | atrx-20191231x10k.htm |
Exhibit 32.2
ADHERA THERAPEUTICS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with this Annual Report on Form 10-K of Adhera Therapeutics, Inc. (the “Company”) for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to her knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
Date: | April 14, 2020 |
By: | /s/ Rhonda Stanley |
Name: | Rhonda Stanley |
Title: | Senior Vice President Finance (Principal Financial Officer) |